Treasury Doubles Bond Buybacks as 30-Year Yield Hit 5.33%

Here's what happened Wednesday in one sentence: the bond market had a meltdown, the US Treasury blinked, and stocks got a sugar high. The 30-year yield hit 5.33%, the highest level since 2007, and Secretary Scott Bessent announced the government would at least double its planned purchases of long-dated debt, targeting bonds from the 10-to-30-year part of the curve. Yields retreated to around 5.18%, Bitcoin bounced, metals surged, and the major indexes closed modestly green, with the S&P 500 up about 17 points and the Russell 2000 outperforming at +0.5%.

The bull case is pretty simple: intervention worked, at least on the day. Treasury pulling yields back from multi-decade highs removes one of the biggest headwinds facing equities, corporate borrowing, and the housing market simultaneously. The move drew comparisons to Operation Twist, and for a few hours it absolutely felt like one.

The bear case, per JPMorgan, is that this is the financial equivalent of duct-taping a crack in a dam. Buybacks address the symptom of high long-term yields without touching the cause: a 6% fiscal deficit running at near-full employment with total public debt now north of $40 trillion. Worse, funding those buybacks requires issuing more short-term paper at the front end, which could ease financial conditions enough to force the Fed to hike rates. Net result: you fix the 30-year yield and accidentally make everything else more expensive. As the Bloomberg coverage put it, there is no real disorder in Treasury markets right now, so doubling down on buybacks is a choice, not a necessity.

Meanwhile, $MRNA decided to completely steal the macro story by surging 177% in a single session after its personalized mRNA cancer vaccine showed positive late-stage results in melanoma treatment, adding $44 billion in market cap and torching $5.5 billion in short positions along the way. That's the kind of move that makes the bond market drama feel like background noise. $MRK tagged along for a 13% gain since the two companies co-developed the treatment.

The bigger rotation picture is actually healthy: healthcare and biotech led on the session while semiconductors pulled back, which TheChartGuys called a classic bull market handoff of sector leadership rather than a warning sign. Metals are in a confirmed breakout, global ETFs are outperforming, and international value names are having their moment without any AI hype propping them up.

The Treasury put is back in play, the cancer cure rally is real, and the bond market is still a live wire. Pick your poison, because apparently we're doing all three at once now.